Patient dosing has begun in a Phase III clinical programme investigating GSK’s 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Invasive Meningococcal Disease (IMD) is uncommon, with country-specific reported cases ranging from 0.1 to 2.4 cases per 100,000 population in 2017. However, the disease can kill in as few as
Now officially classified as a global health threat by the WHO, the Coronavirus epidemic is showing no signs of slowing down. Over 28,000 cases have been confirmed around the world to date, with more than 20 nations reporting cases, some of which also include locals who had not even traveled to China. As a result,
GSK announce promising results from a study conducted in partnership with non-profit scientific research organisation IAVI, that is investigating the efficacy of the company’s tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection. The study was conducted across 11 sites throughout Kenya, South Africa and Zambia, which are all TB-endemic regions, and enrolled over
GSK announced results from its PRIMA Phase III trial, in which niraparib was studied as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. The data showed that the drug resulted in a 38% reduction in the risk of disease progression or death in the overall population, driven by
IR35 rules are designed to stop tax avoidance by workers who provide services to clients via a limited company rather than as employees. A contractor operating through a Limited company but otherwise practically operating as an employee is considered to be a “disguised employee”. HMRC stated there is evidence that contractors in the pharmaceutical industry
GSK presents new data showing that its asthma drug Nucala can significantly improve quality of life and lung function in patients with severe, eosinophilic form of asthma. The Phase IIIb MUSCA study had met all its primary and secondary endpoints successfully, showing that when the treatment was added to standard of care, patients experienced significant
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, with the aim to run clinical trials of Adaptimmune’s potential immunotherapy as a treatment for one of the rarest soft tissue cancers in the world.
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to bone drugs Prolia, Xgeva and cancer therapy Vectibix in 48 countries around the globe.
GlaxoSmithKline (GSK) have confirmed that they are trying to compress the clinical trials of their potential Ebola vaccine into just 12 months. Normally it could take up to ten years to run clinical trials, with it typically taking 6 to 11 months to move an experimental vaccine from preclinical testing into clinical trials. However, due
David Willetts, the UK’s Science Minister, yesterday announced an investment of £52 million for the UK’s science sectors to improve skills and vocational training. The announcement was made at the official launch of the Science and Industrial Partnership (SIP), which is being led by GlaxoSmithKline (GSK). The announcement is expected to create over ‘7,800 education
